Trial Profile
Quality enhancement research initiative (QERI) in the dyslipidemia management strategy involving ezetimibe with statin in high risk patients who have not achieved recommended LDL [low-density lipoprotein] targets
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2019
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms GUIDE
- 13 May 2008 Status changed from in progress to completed on clinicaltrials.gov
- 31 Oct 2007 Status changed from recruiting to in progress.
- 14 Dec 2006 New trial record.